Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Muhsen, Khitam ^a,d   Lagos, Rosanna ^b   Reymann, Mardi K ^a   Graham, David Y ^c   Pasetti, Marcela F ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HOSPITAL ROBERTO DEL RÍO   (Chile)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; LIPOPOLYSACCHARIDE; PEPSINOGEN I; PEPSINOGEN II; PEPSINOGEN;

AGE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEROCONVERSION; SHIGELLA FLEXNERI; SHIGELLOSIS; BLOOD; CHILE; HELICOBACTER PYLORI; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; CHILD; CHILD, PRESCHOOL; CHILE; CHOLERA VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPSINOGEN A;

EID: 84898640574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083999     Document Type: Article

References (47)

1. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, et al. (1996) Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial. United State (Pubitemid 26012601)
2. Jiang V, Jiang B, Tate J, Parashar UD, Patel MM (2010) Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin 6:532-542.
3. Levine MM, Ferreccio C, Black RE, Germanier R (1987) Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1:1049-1052. (Pubitemid 17061327)
4. Cryz SJ Jr, Levine MM, Kaper JB, Furer E, Althaus B (1990) Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8:577-580.
5. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, et al. (1999) Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 67:6341-6345.
6. Kotloff KL, Wasserman SS, Odonnell S, Losonsky GA, Cryz SJ, et al. (1992) Safety and Immunogenicity in North Americans of a Single Dose of Live Oral Cholera Vaccine Cvd 103-Hgr - Results of a Randomized, Placebo-Controlled, Double-Blind Crossover Trial. Infection and Immunity 60:4430-4432.
7. Levine MM (2010) Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8:129.
8. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, et al. (1999) Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 180:1709-1712. (Pubitemid 29506480)
9. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, et al. (1992) Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 165:1042-1048.
10. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, et al. (1992) Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340:689-694.
11. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, et al. (1993) Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 61:3994-3997. (Pubitemid 23260079)
12. Lagos R, Avendano A, Prado V, Horwitz I, Wasserman S, et al. (1995) Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 63:707-709.
13. Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, et al. (2000) Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 182:1199-1206.
14. Torres J, Perez-Perez G, Goodman KJ, Atherton JC, Gold BD, et al. (2000) A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res 31:431-469. (Pubitemid 32117619)
15. Guariso G, Basso D, Bortoluzzi CF, Meneghel A, Schiavon S, et al. (2009) GastroPanel: evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children. Clin Chim Acta 402:54-60.
16. Kalach N, Legoedec J, Wann AR, Bergeret M, Dupont C, et al. (2004) Serum levels of pepsinogen I, pepsinogen II, and gastrin-17 in the course of Helicobacter pylori gastritis in pediatrics. J Pediatr Gastroenterol Nutr 39:568-569.
17. De Angelis GL, Cavallaro LG, Maffini V, Moussa AM, Fornaroli F, et al. (2007) Usefulness of a serological panel test in the assessment of gastritis in symptomatic children. Dig Dis 25:206-213. (Pubitemid 350194169)
18. Kolvusalo AI, Pakarinen MP, Kolho KL (2007) Is Gastro Panel serum assay useful in the diagnosis of Helicobacter pylori infection and associated gastritis in children? Diagnostic Microbiology and Infectious Disease 57:35-38. (Pubitemid 44908830)
19. Lopes AI, Palha A, Lopes T, Monteiro L, Oleastro M, et al. (2006) Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H-pylori virulence factors in a paediatric population. Scandinavian Journal of Gastroenterology 41:524-531.
20. Oderda G, Vaira D, Dell'Olio D, Holton J, Forni M, et al. (1990) Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori. J Clin Pathol 43:762-765. (Pubitemid 20279707)
21. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, et al. (1995) Longterm sequelae of Helicobacter pylori gastritis. Lancet 345:1525-1528.
22. Ganga-Zandzou PS, Michaud L, Vincent P, Husson MO, Wizla-Derambure N, et al. (1999) Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Pediatrics 104:216-221. (Pubitemid 29362126)
23. Prado V, Lagos R, Nataro JP, San Martin O, Arellano C, et al. (1999) Population-based study of the incidence of Shigella diarrhea and causative serotypes in Santiago, Chile. Pediatr Infect Dis J 18:500-505. (Pubitemid 29277612)
24. Lagos R, Losonsky G, Abrego P, San Martin O, Prado V, et al. (1996) Tolerancia, inmunogenicidad, excreción y transmisión de la vacuna anti-cólera oral viva-atenuada, CVD 103-HgR. Estudio pareado doble ciego en niños chilenos de 24 a 59 meses Boletín Médico del Hospital Infantil de México 214-220.
25. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, et al. (1999) Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J 18:624-630. (Pubitemid 29350330)
26. Kindermann A, Konstantopoulos N, Lehn N, Demmelmair H, Koletzko S (2001) Evaluation of two commercial enzyme immunoassays, testing immunoglobulin G (IgG) and IgA responses, for diagnosis of Helicobacter pylori infection in children. J Clin Microbiol 39:3591-3596. (Pubitemid 32954507)
27. Nurgalieva ZZ, Opekun AR, Graham DY (2006) Problem of distinguishing false-positive tests from acute or transient Helicobacter pylori infections. Helicobacter 11:69-74. (Pubitemid 43363304)
28. Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, et al. (2004) Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. Journal of Infectious Diseases 190:1745-1754. (Pubitemid 39487817)
29. Fix AD, San Martin O, Gallicchio L, Vial PA, Lagos R (2002) Age-specific prevalence of antibodies to hepatitis A in Santiago, Chile: Risk factors and shift in age of infection among children and young adults. American Journal of Tropical Medicine and Hygiene 66:628-632.
30. Hopkins RJ, Vial PA, Ferreccio C, Ovalle J, Prado P, et al. (1993) Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis 168:222-226. (Pubitemid 23178755)
31. Frenck RW Jr, Clemens J (2003) Helicobacter in the developing world. Microbes Infect 5:705-713. (Pubitemid 36695145)
32. Kato S, Sherman PM (2005) What is new related to Helicobacter pylori infection in children and teenagers? Arch Pediatr Adolesc Med 159:415-421. (Pubitemid 40632129)
33. Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347:1175-1186.
34. Atherton JC (2006) The pathogenesis of Helicobacter pylori-induced gastroduodenal diseases. Annu Rev Pathol 1:63-96.
35. Atherton JC, Blaser MJ (2009) Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 119:2475-2487.
36. Sack GH Jr, Pierce NF, Hennessey KN, Mitra RC, Sack RB, et al. (1972) Gastric acidity in cholera and noncholera diarrhoea. Bull World Health Organ 47:31-36.
37. Schiraldi O, Benvestito V, Di Bari C, Moschetta R, Pastore G (1974) Gastric abnormalities in cholera: epidemiological and clinical considerations. Bull World Health Organ 51:349-352.
38. Gitelson S (1971) Gastrectomy, achlorhydria and cholera. Isr J Med Sci 7:663-667.
39. Giannella RA, Broitman SA, Zamcheck N (1973) Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 78:271-276.
40. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N (1997) How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 113:S43-S49.
41. Clemens J, Albert MJ, Rao M, Qadri F, Huda S, et al. (1995) Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera. J Infect Dis 171:1653-1656.
42. Shahinian ML, Passaro DJ, Swerdlow DL, Mintz ED, Rodriguez M, et al. (2000) Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet 355:377-378.
43. Leon-Barua R, Recavarren-Arce S, Chinga-Alayo E, Rodriguez-Ulloa C, Taylor DN, et al. (2006) Helicobacter pylori-associated chronic atrophic gastritis involving the gastric body and severe disease by Vibrio cholerae. Trans R Soc Trop Med Hyg 100:567-572.
44. Harris PR, Wright SW, Serrano C, Riera F, Duarte I, et al. (2008) Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 134:491-499. (Pubitemid 351173044)
45. Fagundes-Neto U, Viaro T, Wehba J, Patricio FRD, Machado NL (1984) Tropical Enteropathy (Environmental-Enteropathy) in Early-Childhood - a Syndrome Caused by Contaminated Environment. Journal of Tropical Pediatrics 30:204-209. (Pubitemid 14049854)
46. Dos Reis JC, De Morais MB, Oliva CA, Fagundes-Neto U (2007) Breath hydrogen test in the diagnosis of environmental enteropathy in children living in an urban slum. Dig Dis Sci 52:1253-1258. (Pubitemid 46626168)
47. Muhsen K, Pasetti MF, Reymann MK, Graham DY, Levine MM (2013) Helicobacter pylori infection affects immune responses following vaccination of typhoid-naïve U. S. adults with attenuated Salmonella Typhi oral vaccine CVD 908-htrA. Journal of Infectious Diseases. In press: doi: 10.1093/infdis/jit625